Steven Tong

Epidemiology, management and outcomes of Cryptococcus gattii infections: A 22-year cohort.

Jennifer A O'Hern, Adrian Koenen, Sonja Janson, Krispin M Hajkowicz, Iain K Robertson, Sarah E Kidd, Robert W Baird, Steven Yc Tong, Joshua S Davis, Phillip Carson, Bart J Currie, Anna P Ralph

Journal article  |  2023  |  PLoS Negl Trop Dis

BACKGROUND: Cryptococcus gattii is a globally endemic pathogen causing disease in apparently immune-competent hosts. We describe a..

PET Scan in S. aureus bacteremia: Peeking Under the Covers.

Todd C Lee, Emily G McDonald, Steven YC Tong

Journal article  |  2023  |  Clin Infect Dis

Detection of Streptococcus pyogenes M1UK in Australia and characterization of the mutation driving enhanced expression of superantigen SpeA.

Mark R Davies, Nadia Keller, Stephan Brouwer, Magnus G Jespersen, Amanda J Cork, Andrew J Hayes, Miranda E Pitt, David MP De Oliveira, Nichaela Harbison-Price, Olivia M Bertolla, Daniel G Mediati, Bodie F Curren, George Taiaroa, Jake A Lacey, Helen V Smith, Ning-Xia Fang, Lachlan JM Coin, Kerrie Stevens, Steven YC Tong, Martina Sanderson-Smith, et al.

Journal article  |  2023  |  Nat Commun

A new variant of Streptococcus pyogenes serotype M1 (designated 'M1UK') has been reported in the United Kingdom, linked with seaso..

Observational versus randomized controlled trials to inform antibiotic treatment durations: a narrative review.

Emily G McDonald, Connor Prosty, Ryan Hanula, Émilie Bortolussi-Courval, Arthur M Albuquerque, Steven YC Tong, Fergus Hamilton, Todd C Lee

Journal article  |  2023  |  Clin Microbiol Infect

BACKGROUND: Studies comparing shorter and longer antibiotic treatment durations are increasingly common. Randomized controlled tri..

Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19

Zoe K McQuilten, Balasubramanian Venkatesh, Vivekanand Jha, Jason Roberts, Susan C Morpeth, James A Totterdell, Grace M McPhee, John Abraham, Niraj Bam, Methma Bandara, Ashpak K Bangi, Lauren A Barina, Bhupendra K Basnet, Hasan Bhally, Khema R Bhusal, Umesh Bogati, Asha C Bowen, Andrew J Burke, Devasahayam J Christopher, Sanjeev D Chunilal, et al.

Journal article  |  2023  |  NEJM Evidence

Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.

Amy Legg, Niamh Meagher, Sandra A Johnson, Matthew A Roberts, Alan Cass, Marc H Scheetz, Jane Davies, Jason A Roberts, Joshua S Davis, Steven YC Tong

Journal article  |  2023  |  Clin Drug Investig

BACKGROUND: Clinical risk factors for nephrotoxicity in Staphylococcus aureus bacteraemia remain largely undetermined, despite its..

Correction to: Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.

Amy Legg, Niamh Meagher, Sandra A Johnson, Matthew A Roberts, Alan Cass, Marc H Scheetz, Jane Davies, Jason A Roberts, Joshua S Davis, Steven YC Tong

Journal article  |  2023  |  Clin Drug Investig

There was an error in the affiliation details for authors Amy Legg, Alan Cass, Jane Davies and Joshua S. Davis. The affiliation wh..

Preventing early childhood transmission of hepatitis B in remote aboriginal communities in Northern Australia.

Richard P Sullivan, Jane Davies, Paula Binks, Melita McKinnon, Roslyn Gundjirryiir Dhurrkay, Kelly Hosking, Sarah Mariyalawuy Bukulatjpi, Stephen Locarnini, Margaret Littlejohn, Kathy Jackson, Steven YC Tong, Joshua S Davis

Journal article  |  2022  |  Int J Equity Health

BACKGROUND: Chronic hepatitis B is a public health concern in Aboriginal communities in the Northern Territory of Australia with p..

Consumer perspectives on simplified, layered consent for a low risk, but complex pragmatic trial.

Tanya J Symons, Nicola Straiton, Rosie Gagnon, Roberta Littleford, Anita J Campbell, Asha C Bowen, Adam G Stewart, Steven YC Tong, Joshua S Davis

Journal article  |  2022  |  Trials

BACKGROUND: For decades, the research community has called for participant information sheets/consent forms (PICFs) to be improved..

ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial.

Justin T Denholm, Balasubramanian Venkatesh, Joshua Davis, Asha C Bowen, Naomi E Hammond, Vivekanand Jha, Grace McPhee, Zoe McQuilten, Matthew VN O'Sullivan, David Paterson, David Price, Megan Rees, Jason Roberts, Mark Jones, James Totterdell, Thomas Snelling, Nanette Trask, Susan Morpeth, Steven Yc Tong, undefined ASCOT ADAPT investigators

Journal article  |  2022  |  Trials

BACKGROUND: SARS-CoV-2 infection is associated with a significant risk of hospitalisation, death, and prolonged impact on quality ..